Mesoblast (MESO) Non-Current Deffered Revenue (2018 - 2025)
Mesoblast recorded quarterly Non-Current Deffered Revenue of $2.5 million in Q4 2025, little changed quarter-over-quarter from $2.5 million in Q2 2025, and little changed year-over-year from $2.5 million in Q4 2024.
Mesoblast's Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $2.5 million for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $2.5 million (changed 0.0% YoY), while the FY2025 annual figure was $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue came in at $2.5 million for Q4 2025 at Mesoblast, roughly flat from $2.5 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.5 million in Q1 2021 to a low of $2.5 million in Q1 2021.
- A 5-year average of $2.5 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2021 and fell as far as 0.0% in 2021.
- Mesoblast's Non-Current Deffered Revenue stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.5 million, and $2.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |
| Mar 31, 2020 | 2.50 Mn |
| Dec 31, 2019 | 10.00 Mn |
| Sep 30, 2019 | 10.00 Mn |
| Jun 30, 2019 | 10.00 Mn |
| Mar 31, 2019 | 10.00 Mn |
| Dec 31, 2018 | 10.00 Mn |
| Sep 30, 2018 | 10.00 Mn |